Superworth

Innospec IOSP

Chemicals, Basic Materials
$99.55
−0.34%
Market cap
$2.5B
PE
20.3×
10y median 22.3×
Forward PE
n/m
not a meaningful number
Price to sales
1.3×
EV/EBIT
12.1×
Revenue, 12 months
$1.8B
+3% on a year ago
Net margin
6.6%
Free cash flow yield
2.9%

Innospec trades at 20.3× trailing earnings, near its ten-year median. Revenue was $1.8B over the last twelve months, up 3% on a year earlier with a 7% net margin.

Charts

Financials

Income statement for IOSP, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$464.1M−10%$494.7M−3%$500.2M−2%$435M−10%$443.4M−5%$466.8M−6%$440.8M−12%$439.7M+1%$441.9M−0%$455.6M−2%$453.2M+3%$491.4M+12%
Cost of revenue$326.9M−8%$339M−6%$344.5M−5%$308.1M−7%$319.3M−2%$330.6M−3%$315.7M−8%$316.5M+3%$325.2M+2%$328.2M−1%$329.7M+4%$353.1M+12%
Gross profit$137.2M−12%$155.7M+3%$155.7M+5%$126.9M−16%$124.1M−10%$136.2M−13%$125.1M−20%$123.2M−3%$116.7M−6%$127.4M−7%$123.5M−1%$138.3M+12%
R&D$11.6M+15%$8.9M+6%$14M+32%$14M+32%$13.6M+17%$14.9M+67%$12.7M−9%$13.6M−3%$13.7M+1%$11M−26%$13.2M+4%$14.2M+4%
SG&A$83.7M−13%$102.3M+6%$90.5M−6%$71.6M−32%$64.3M−23%$78.9M−23%$69.3M−23%$74.6M+4%$71.9M+12%$69.3M−12%$78.5M+13%$84.3M+13%
$41.9M−16%$44.5M−5%$50.5M+23%$40.7M+19%$45.6M+9%$41.1M−8%$42.5M−16%$34.3M−16%$5.9M−87%$46.8M+14%$36.5M−14%$39.7M+16%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income$47.5M−3%$45.3M+0%$55.3M+23%$43.7M+19%$44.8M−6%−$102.6M$45.2M−18%$32.3M−26%$11.5M−74%$50.3M$39.9M−12%$41.6M+29%
$8.3M−19%$7.5M−62%$13.9M+18%$12.5M+62%$11.4M+37%−$32.2M$11.6M−17%$8.4M−33%−$1.4M$2.9M$9.1M−22%$10.4M+24%
Net income$39.2M+1%$37.8M+48%$41.4M+25%$31.2M+8%$33.4M−15%−$70.4M$32.8M−21%$23.5M−25%$12.9M−61%$47.4M$30.4M−7%$30.8M+31%
$1.57+1%$1.51+48%$1.65+24%$1.24+7%$1.33−15%−$2.82$1.31−21%$0.94−24%$0.52−61%$1.91$1.22−7%$1.25+33%
25M+0%25.1M+0%25.1M+0%25.1M+1%25.1M+0%24.9M−1%25.1M+0%25M−0%24.9M−1%24.8M−0%24.8M−1%24.7M−1%

EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 14 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Chemicals nearest Innospec's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
IOSPInnospec$2.5B20.3×22.3×1.3×+3%6.6%
NGVTIngevity$2.5B50.1×20.1×2.2×−4%4.7%
ROGRogers$2.3B50.7×34.4×2.7×+7%5.3%
FULFuller H B$2.8B14.4×22.8×0.8×+1%5.6%
WDFCWD 40$3.1B37.5×39.2×4.4×+11%12.0%
CBTCabot$3.9B21.4×14.4×1.1×−5%5.2%
AVNTAvient$4B23.5×20.3×1.2×+2%5.1%
CSWCSW Industrials$4.7B36.9×34.8×3.7×+30%10.2%
CRONCronos$1.2B16.6×24.9×6.9×+37%39.1%
BCPCBalchem$5.5B32.9×40.9×5.0×+9%15.4%
HXLHexcel$6.1B40.8×36.2×3.1×+5%7.8%
Peer median$3.5B34.9×29.6×2.9×+6%6.7%

More on Innospec

Each number over time

Where it ranks

Its groups

About

Industry
Chemicals
Sector
Basic Materials

Valuation data, not investment advice. Prices as of .